Crossmark

Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus

Crossref DOI link: https://doi.org/10.1007/s40258-020-00603-7

Published Online: 2020-08-12

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hu, Shanshan

Deng, Xun

Ma, Yanjiao

Li, Zhilei

Wang, Yuhang

Wang, Yong
Funding

Funding for this research was provided by:

the National Natural Science Foundation of China (81302738)

WU JIEPING MEDICAL FOUNDATION of China (320.6750.2020-04-22)
License Information

Text and Data Mining valid from 2020-08-12

Version of Record valid from 2020-08-12
More Information

Article History

First Online: 12 August 2020

Declarations

:

: This work was supported by the Wu Jieping Medical Foundation of China (Grant numbers 320.6750.2020–04-22).

: The authors declare that they have no conflict of interest.

: Not applicable.

: YW and SH contributed to the study conception and design. Material preparation, data collection and analysis were performed by SH and YW. YM and ZL supervised the process of data collection and analysis. The first draft of the manuscript was written by SH and XD and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

: The data and materials generated or analysed during this study are available from the corresponding author on reasonable request.

: The manuscript is approved by all authors for publication.

Document is current

Any future updates will be listed below